Clinical trials: Solid Tumor, completed
Unspecified Adult Solid Tumor, Protocol Specific
LY293111 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of LY293111 in treating patients who have advanced solid…
- Trial name
- NCT00006375
- Testing
- LY293111
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Supportive Care, Metastatic Cancer
Feasibility of Supportive Care Needs in Patients With Advanced Solid Cancer in a Therapeutic Trial
The purpose of the study is to assess the supportive care needs of patients enrolled in a therapeutic trial for metastatic cancer.
- Conditions
- Supportive Care, Metastatic Cancer, Clinical Trial
- Trial name
- ES4-UIC (NCT04896099)
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Institut Curie
Breast Cancer, Colorectal Cancer
Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer
- Trial name
- NCT00369109
- Testing
- biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Advanced Solid Tumor, Pain
Meaning-Centered Pain Coping Skills Training
This study is a randomized clinical trial of a psychosocial pain management intervention called, Meaning-Centered Pain Coping Skills Training (MCPC).
- Trial name
- NCT04431830
- Testing
- Meaning-Centered Pain Coping Skills Training
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Colorectal Cancer, Solid Cancers
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Colorectal Cancer, Solid Cancers, Gastric Cancer
- Trial name
- NCT05396300
- Testing
- Intraperitoneal infusion of FAST CEA-targeted CAR-T, CEA CAR-T cells
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Weijia Fang, MD
Unspecified Adult Solid Tumor, Protocol Specific
Health Education in Improving the Understanding of Medical Information
RATIONALE: Understanding the risk of disease and prevention and screening activities to lower disease risk may help individuals make informed medical decisions.
- Trial name
- NCT00387998
- Testing
- AHRQ staying healthy booklet, Risk primer
- Volunteers
- 555 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer, Gestational Trophoblastic Tumor
Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors
RATIONALE: Interleukin-11 and filgrastim stimulate the production of blood cells. Giving these drugs to stimulate peripheral stem cells that can be collected for peripheral stem cell transplantation may result in fewer side…
- Conditions
- Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma
- Trial name
- NCT00004157
- Testing
- filgrastim, recombinant interleukin-11
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer, Tumors
An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
To determine the feasibility and safety of administering YM155 in combination with docetaxel
- Trial name
- NCT00514267
- Testing
- YM 155, Docetaxel, Prednisone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Astellas Pharma Inc
Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CMG901.
- Conditions
- Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer
- Trial name
- NCT04805307
- Testing
- CMG901
- Where
- 32 sites in China
- Volunteers
- 176 people
- Sponsor
- Keymed Biosciences Co.Ltd
Advanced Solid Tumors
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
This is an open-label study designed to determine the recommended Phase 2 dose (RPTD) and evaluate the safety and pharmacokinetics of ABT-806 in subjects with advanced solid tumors.
- Trial name
- NCT01255657
- Testing
- ABT-806
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
To assess the duration of severe neutropenia (DSN) in treatment Cycle 1 in patients treated with docetaxel (75 mg/m2) + plinabulin (5, 10, or 20 mg/m2) or with docetaxel (75 mg/m2) + pegfilgrastim (6 mg).
- Trial name
- NCT04345900
- Testing
- Plinabulin, Pegfilgrastim
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 55 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Solid Tumors
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.
- Trial name
- NCT03477175
- Testing
- E7080, Comparator Drug, Comparator Drug: Sorafenib
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 40 people
- Sponsor
- Eisai Inc.
Advanced Stage Solid Tumors
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).
- Trial name
- NCT06255665
- Testing
- JNJ-79032421
- Where
- 3 sites in Spain
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
Neoplasms
GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)
This is a first time in human (FTIH), open-label, non-randomized, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of GSK3174998…
- Trial name
- NCT02528357
- Testing
- GSK3174998, Pembrolizumab
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
Relapsed or Refractory Solid Tumors
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory solid tumors. Study includes a dose escalation phase and expansion phase.
- Trial name
- NCT01778439
- Testing
- OMP-52M51
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Solid Tumors
Study of KRN951 in Patients With Solid Tumors
The purpose of this study is to assess the safety and tolerability of KRN951 administered to patients with solid tumors. In the single dose period, patients in each cohort will receive one oral dose of KRN951 in the first day…
- Trial name
- NCT00970411
- Testing
- KRN951
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Advanced Solid Tumors, Melanoma
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
A multicenter, open-label, phase 1b/2 study to evaluate the safety and efficacy of AK104, a PD-1 and CTLA-4 bispecific antibody, in selected advanced solid tumors.
- Trial name
- NCT04172454
- Testing
- AK104
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Akeso
Advanced Cancer, Solid Tumor
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with either everolimus or temsirolimus. The safety of these drug combinations will also be studied.
- Trial name
- NCT01596140
- Testing
- Vemurafenib, Everolimus, Temsirolimus
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to < 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA…
- Conditions
- Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm, CNS Tumor
- Trial name
- NCT04773782
- Testing
- avapritinib
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 29 people
- Sponsor
- Blueprint Medicines Corporation
Neuroblastoma, Sarcoma
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
RATIONALE: A peripheral stem cell, bone marrow, or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy.
- Conditions
- Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00112645
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Milton S. Hershey Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.